NGeneBio, a corporations in next-generation sequencing (NGS) precision diagnostics, said on the 8th it signed an exclusive technology transfer agreement for the "next-generation laboratory information system (NGLIS)," co-developed with Asan Medical Center.
NGLIS is an information management platform that links a hospital's electronic medical records (EMR) and genome analysis software into a single system. It automates the process from receiving genetic tests to analysis and results management, reducing input errors and allowing the application of standardized analytical procedures. It also includes a structure that can analyze DNA and RNA simultaneously.
The core of this system is the consolidation of a patient's clinical information and genomic analysis data into a single workflow. It is configured so that medical records, test results, and genetic analysis information are managed together without being separated, making data use and tracking easy, the company said.
NGeneBio plans to expand this platform by adding pathology image data and artificial intelligence (AI) analysis functions, evolving it into a data-integration structure that handles clinical, genomic, and pathology information together.
With this agreement, the company will also push in stages for the supply of NGLIS and the application of its in-house multimodal medical data platform "G-Hub," focusing on existing transaction hospitals and overseas partner hospitals. G-Hub is a platform that collects, manages, and analyzes various medical data generated in hospitals in a cloud environment, aiming to use multiple forms of data together.
A company official said, "Starting with an AI model that helps analyze gene mutations, G-Hub will gradually add AI functions that support medical data analysis, including clinical trial subject matching and predicting responses to immuno-oncology treatments."
NGeneBio plans to de-identify and standardize real-world data (RWD) generated in actual clinical workflows at hospitals that adopt NGLIS, in accordance with relevant laws and security standards, and accumulate it in G-Hub. Through this, the company is reviewing ways to provide hospitals with data analysis tools that support research and personalized treatment, and to provide corporations in pharmaceuticals and biotech with data-based services that can be used for new drug development and clinical trials.
This business structure is similar to the case of Tempus AI, which grew into a medical data platform corporations in the United States. Tempus AI expanded its business into medical AI and the Precision Medicine data field by accumulating clinical and genomic data based on genomic testing services.
NGeneBio aims to increase the share of its data-driven business by combining its in-house NGS panel development and manufacturing capabilities with a data collection structure through NGLIS and expanding it to the G-Hub platform. In particular, the strategy is to secure data competitiveness that reflects the genomic characteristics of Asians, centered on patient data accumulated at tertiary general hospitals in Korea and at medical institutions in Asia, including Vietnam and Thailand.
Chief Executive Kim Min-sik of NGeneBio said, "The technology transfer with Asan Medical Center is meaningful in that it is based on a system used in clinical settings," and "we plan to build a platform that can be used in research and industry through the accumulation and use of medical data."